Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001049159 | SCV001213193 | uncertain significance | Long QT syndrome | 2023-12-15 | criteria provided, single submitter | clinical testing | This variant, c.3105_3107dup, results in the insertion of 1 amino acid(s) of the KCNH2 protein (p.Gly1036dup), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (no rsID available, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with KCNH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 845975). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002320277 | SCV002605932 | uncertain significance | Cardiovascular phenotype | 2024-03-14 | criteria provided, single submitter | clinical testing | The c.3105_3107dupGGG variant (also known as p.G1036dup), located in coding exon 13 of the KCNH2 gene, results from an in-frame duplication of GGG at nucleotide positions 3105 to 3107. This results in the duplication of an extra glycine residue between codons 1036 and 1037. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Based on the available evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002479301 | SCV002782096 | uncertain significance | Short QT syndrome type 1; Long QT syndrome 2 | 2021-11-03 | criteria provided, single submitter | clinical testing |